ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "SLE"

  • Abstract Number: 41 • 2013 ACR/ARHP Annual Meeting

    Targeting Cereblon With The High Affinity Immunomodulatory Compound CC-220: A Novel Therapeutic Agent For Autoimmunity

    Peter Schafer1, Emily Rychak2, Derek Mendy3, Stacey Parton1, Lori Capone4, Antonia Lopez-Girona2, Dorota Cedzik5, Jolanta Kosek5, Ling-Hua Zhang5 and Rajesh Chopra5, 1Department of Translational Development, Celgene Corporation, Summit, NJ, 2Molecular & Medical Science, Celgene Signal Research, San Diego, CA, 3Celgene Signal Research, San Diego, CA, 4Celgene Corporation, Summit, NJ, 5Translational Development, Celgene Corporation, Summit, NJ

    Background/Purpose: Cereblon (CRBN) is a component of the E3 ubiquitin ligase complex including CUL4A, DDB1, and ROC-1. CC-220 is a novel immunomodulatory compound currently in…
  • Abstract Number: 2894 • 2013 ACR/ARHP Annual Meeting

    Triggering Receptor Expressed on Myeloid Cells 1 In Systemic Lupus Erythematosus

    Laurie Davis1, Yong Du2, Tianfu Wu3 and Chandra Mohan4, 1Internal Medicine, UT Southwestern Medical Center, Dallas, TX, 2Internal Medicine - Rheumatic Diseases, University of Texas, Southwestern Medical Center at Dallas, Dallas, TX, 3Division of Rheumatology/Internal Medicine, University of Texas, Southwestern Medical Center at Dallas, Dallas, TX, 4University of Houston, Houston, TX

    Background/Purpose: In healthy individuals, TREM-1 proteins are cell surface receptors expressed by hematopoietic cells of the myeloid lineage. TREM-1 is a potent amplifier of proinflammatory…
  • Abstract Number: 1699 • 2013 ACR/ARHP Annual Meeting

    Development Of Systemic Lupus Erythamatosus Among “Possible Systemic Lupus Erythamatosus ” Patients Seen In Consultation: Long-Term Follow-Up

    May Al Daabil1, Bonnie L. Bermas1, Tabatha Norton1, Hsun Tsao1, Patricia Ho1, Joseph F. Merola1, Peter H. Schur1, Elena M. Massarotti1 and Karen H. Costenbader2, 1Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 2Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: Rheumatology consultation to rule out SLE is common. However, in a substantial proportion of patients, SLE can be neither confirmed nor ruled out at…
  • Abstract Number: 1567 • 2013 ACR/ARHP Annual Meeting

    Desensitization To Trimethoprim/Sulfamethoxazole In Systemic Lupus Erythematosus Patients : A Retrospective Cohort Study

    Yasuhiro Suyama1, Mitsumasa Kishimoto1, Hiroto Nakano2, Chisun Min3, Yoichiro Haji1, Ryo Rokutanda1, Yuri Ohara1, Hisanori Shimizu1, Ken-ichi Yamaguchi4, Yukio Matsui4, Kazuo Matsui2 and Masato Okada4, 1Division of Allergy & Rheumatology, St. Luke's International Hospital, Tokyo, Japan, 2Department of Rheumatology, Kameda Medical Center, Kamogawa, Japan, 3Division of Allergy and Rheumatology, St. Luke's International Hospital, Tokyo, Japan, 4Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan

    Background/Purpose: A high incidence of trimethoprin-sulfamethoxazole (TMP/SMX) hypersensitivity is reported in patients with systemic lupus erythematosus (SLE), and reactions are often severe. Desensitization protocol is…
  • Abstract Number: 636 • 2013 ACR/ARHP Annual Meeting

    Neutrophil-Mediated Interferon Activation In Systemic Lupus Erythematosus Bone Marrow

    Anna Bird1, Nida Meednu2, Javier Rangel-Moreno3, Srilakshmi Yalavarthi4, Jennifer Barnard1, Teresa Owen5, Jason S. Knight6, Alfred Rabinovich1, Arumugam Palanichamy2, Jane Liesveld7, Jason W Bauer8, Emily Baechler9, Mariana J. Kaplan10 and Jennifer H. Anolik11, 1Medicine-Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, 2Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, 3Medicine- Allergy, Immunology, and Rheumatology, University of Rochester, Rochester, NY, 4University of Michigan Rheumatology, Ann Arbor, MI, 5Medicine- Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, NY, 6Department of Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, 7Hematology/Oncology, University of Rochester Medical Center, Rochester, NY, 8University of Minnesota, Minneapolis, MN, 9Medicine, University of Minnesota, Minneapolis, MN, 10Systemic Autoimmunity Branch, National Institutes of Health/NIAMS, Bethesda, MD, 11Medicine- Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY

    Background/Purpose: Although SLE is known to be associated with a type I interferon signature in the peripheral blood, the precise site and mechanism of IFN…
  • Abstract Number: 25 • 2013 ACR/ARHP Annual Meeting

    SLE Flares Are Characterized By Generalized Polyclonal Expansions Of Antibody Secreting Cells Without Preference For Autoimmune Responses

    H. Travis Ichikawa, Medicine, Emory University, Atlanta, GA

    Background/Purpose: Increased circulating antibody secreting cells (ASC), including both CD138- plasmablasts and CD138+ plasma cells (PB/PC), correlate with SLE activity and are prominent during Lupus…
  • Abstract Number: 2796 • 2013 ACR/ARHP Annual Meeting

    Effects Of BAFF Inhibition On B Cell Selection In Murine SLE

    Alexis Boneparth1,2, Ramalingam Bethunaickan3, Weiqing Huang4 and Anne Davidson4, 1Pediatrics, The Children's Hospital at Montefiore, Bronx, NY, 2Feinstein Institute for medical Research, Manhasset, NY, 3Autoimmunity, Feinstein Institute for Medical Research, Manhasset, NY, 4Autoimmunity and Musculoskeletal Diseases, Feinstein Institute for Medical Research, Manhasset, NY

    Background/Purpose: BAFF inhibition is a new B cell targeted therapy approved for the treatment of moderately active SLE. Although BAFF regulates selection of naïve autoreactive…
  • Abstract Number: 1646 • 2013 ACR/ARHP Annual Meeting

    Alterations In Circulating T Follicular Helper Cells and T Regulatory Cells In Autoimmune Rheumatic Diseases Treated With B Cell Depletion Therapy: Rituximab

    Pamela M.K Lutalo1,2, Yuan Zhao2, Lee Meng Choong1, Shirish Sangle1, Jo Spencer3 and David P. D'Cruz4, 1Louise Coote Lupus Unit, St Thomas' Hospital, London, United Kingdom, 2Peter Gorer Department of Immunobiology, School of Medicine, King's College London, London, United Kingdom, 3Peter Gorer Department of Immunobiology, King's College London, School of Medicine, London, United Kingdom, 4Louise Coote Lupus Unit, Louise Coote Lupus Unit, St Thomas' Hospital, London, United Kingdom

    Background/Purpose: Granulomatosis with polyangiitis (GPA) and systemic lupus erythematosus (SLE) are autoimmune rheumatic diseases which develop due to failure of immune self-tolerance. T follicular helper…
  • Abstract Number: 1571 • 2013 ACR/ARHP Annual Meeting

    Efficacy Of Tacrolimus Combination Therapy During The Maintenance Phase Of Systemic Lupus Erythematosus

    Kumiko Ohtsuka1, Yusuke Miwa1, Nao Oguro2, Yoko Miura1, Sho Ishii1, Shinya Seki1, Hidekazu Furuya1, Ryo Yanai1, Ryo Takahashi1, Kuninobu Wakabayashi1, Nobuyuki Yajima1 and Tsuyoshi Kasama1, 1Div of Rheumatology, Showa University School of Med, Shinagawa-ku Tokyo, Japan, 2Div of Rhemuatology, Showa University School of Med, Shinagawa-ku Tokyo, Japan

    Background/Purpose: In Japan, a placebo-controlled clinical trial was undertaken to investigate the efficacy and safety of tacrolimus (TAC) for lupus nephritis. Based on the results…
  • Abstract Number: 637 • 2013 ACR/ARHP Annual Meeting

    Proteomic Approach and Validation Of Urinary Biomarkers In Lupus Nephritis

    Joo Youn Lee1, Sung Hae Chang2, Hye Jin Oh3, Yong Yook Lee1, Min Jueng Kang1, Eun Young Lee4, Eun Bong Lee5, Eugene C. Yi1 and Young Wook Song1,5, 1Department of Molecular Medicine and Biopharmaceutical Sciences, Seoul National University, Seoul, South Korea, 2Internal Medicine Rheumatology, Seoul National University Bundang Hospital, Seongnam-si, South Korea, 3Seoul National University, Seoul, South Korea, 4Internal medicine, Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea, 5Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea

    Background/Purpose: Renal involvement occurs in about half of systemic lupus erythematosus (SLE) patients. A number of biochemical markers are currently used to clinically assess lupus…
  • Abstract Number: 31 • 2013 ACR/ARHP Annual Meeting

    IgD- CD27- B Cells From Systemic Lupus Erythematous Patients Have Increased Expression Of Genes Involved In RNA Sensing and Toll-Like Receptor 3 Signaling Pathways

    Scott Jenks1, Edward Ramos2 and Ignacio Sanz3, 1Allergy, Immunology, and Rheumatology, Emory University School of Medicine, Atlanta, GA, 2Biology, Emory University, Atlanta, GA, 3Allergy, Immunology and Rheumatology, Emory University School of Medicine, Atlanta, GA

    Background/Purpose: SLE patients have perturbations in B cell subsets including a large expansion of IgD-CD27- B cells (DN) in patients with active disease. Patients also…
  • Abstract Number: 931 • 2012 ACR/ARHP Annual Meeting

    Health Care Utilization Among Medicaid Enrollees with Systemic Lupus Erythematosus Preceding the Development of End-Stage Renal Disease: Sociodemographic Variation

    Candace H. Feldman1, Linda T. Hiraki2, Graciela S. Alarcon3, Jinoos Yazdany4, Jun Liu5, Michael A. Fischer6, Wolfgang C. Winkelmayer7 and Karen H. Costenbader8, 1Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 2Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital/ Harvard School of Public Health, Boston, MA, 3Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 4Medicine, University of California, San Francisco, San Francisco, CA, 5Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, Boston, MA, 6Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, 7Division of Nephrology, Stanford University School of Medicine, Stanford, CA, 8Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: Extreme sociodemographic disparities exist among systemic lupus erythematosus (SLE) patients in the development of end-stage renal disease (ESRD) from lupus nephritis. Better resource allocation…
  • « Previous Page
  • 1
  • …
  • 36
  • 37
  • 38
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology